-
Aripiprazole oral solution is planned to be included in the priority review
Time of Update: 2021-06-30
On June 15th, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that the aripiprazole oral solution of Sichuan Otsuka Pharmaceutical Co.
-
The "Medical Security Law" will land!
Time of Update: 2021-06-30
616 615，《<（）>》，，、。 《》，，，“”，，。 《》 《》。，、、。 ，、“”，《<>》，《》，、、。 8，“5326”，《<>》，《》。 《（）》，，： 、，，；，15；、，。 ，，；，，12；，61；、，。 ，，25；61，；，。 ，，50%1，5，。 、，；，；，312。 ，《》，，，、、、、，。 ，。，
-
Changchun Hi-tech’s share price plummeted under the "fog" of growth hormone gathering, chairman of the board increased his holdings of 5700 shares
Time of Update: 2021-06-30
Regarding the above two negatives, the Changchun High-tech Investor Communication Department stated that the company's production and operation are normal, and the reason for the stock price fluctuations is mainly attributed to the rumors of "growth hormone" centralized procurement .
-
1.95 billion yuan to acquire Shengxiang Biological and become the largest shareholder of Kehua Biological
Time of Update: 2021-06-30
Because of the industry development opportunities brought about by the new crown epidemic, Shengxiang Bio, which was listed on the Science and Technology Board in August last year, has become the "performance growth king" in the IVD field .
-
Hong Kong and the Mainland sign the "Cooperative Arrangement in the Field of Chinese Medicine Testing and Standard Research"
Time of Update: 2021-06-30
Medicine, medicine, medicine The Director of the Department of Health of the Special Administrative Region Government, Chen Hanyi, pointed out that in recent years, the Special Administrative Region Government has actively promoted exchanges and cooperation in the field of Chinese medicine testing and reference standard research with relevant mainland institutions .
-
Potential "first-in-class" oral antidepressants reach phase 3 clinical endpoints
Time of Update: 2021-06-30
On June 15, 2021, Sage Therapeutics and Biogen jointly announced that the potential "first-in-class" oral drug zuranolone (SAGE-217/BIIB125) for patients with major depression (MDD) is in a phase 3 clinical trial The primary end point was reached .
-
The State Food and Drug Administration and the Hong Kong Department of Health signed a new agreement on Chinese medicine testing
Time of Update: 2021-06-30
On the 15th, the State Food and Drug Administration issued an announcement stating that it had recently signed the "Cooperative Arrangement in the Field of Chinese Medicine Testing and Standard Research" with the Hong Kong Department of Health .
-
Medical Security Law Soliciting Opinions: 6 items including health check-ups are not included in medical insurance
Time of Update: 2021-06-30
Medical Network News, June 16 Yesterday, the National Medical Insurance Bureau issued an announcement on its official website to formally solicit public opinions on the "Medical Security Law (Draft f
-
Innovative drugs, vaccines, CDMO, and the IPOs of major new forces last Wednesday, who is stronger?
Time of Update: 2021-06-30
According to the prospectus of Olin Biotechnology, it is a biopharmaceutical company focusing on the research and development, production and sales of human vaccines .
-
The raw material price of Zishen Yutai Pills has risen, and the price of Codonopsis pilosula overproduction is low!
Time of Update: 2021-06-30
3 The pressure of raw material supply lies in Rehmannia, Dodder and Dipsacus After evaluating the historical price fluctuations, production, supply and demand of Zishen Yutai Pills, Tiandi Yuntu's big data platform for the pharmaceutical industry found that the varieties with the highest supply pressure are Rehmannia glutinosa, Dodder and Dipsacus, especially Rehmannia, and the market has fluctuated greatly this year.
-
Approval of Changchun Pharmaceutical Import Port Can Reduce People's Drug Purchase Cost
Time of Update: 2021-06-30
(Finish) Pharmaceutical Net, June 16 News reporter learned from the Department of Commerce of Jilin Province on the 15th that the Changchun drug import port has been approved for operation, ending the history of "imported drugs and no drug imports" in Jilin Province .
-
APL-1202 and tislelizumab combined treatment of new drug clinical research application approved by FDA
Time of Update: 2021-06-30
On June 15, Yahong Pharmaceutical announced that the new drug clinical research application of APL-1202 and tislelizumab combined with neoadjuvant treatment of myometrial invasive bladder cancer (MIBC) was approved by the FDA.
-
Baiyang Pharmaceutical's IPO plans to publicly issue 52.6 million shares, preliminary inquiry on June 15
Time of Update: 2021-06-30
On June 9th, Baiyang Pharmaceutical issued an initial public offering of shares and listed on the Growth Enterprise Market.
942 million shares, accounting for the total initial issuance after deducting the initial strategic allotment.
-
From a monopoly of 3.5 billion to less than 200 million Bayer was besieged by 23 companies including CSPC
Time of Update: 2021-06-30
On June 3, the day after the fifth batch of centralized procurement documents were released, Eli Lilly announced that it had signed an agreement with Menarini, an Italian pharmaceutical company, to sell Cialis (tadalafil) to the Chinese mainland market.
-
Changchun promotes "family doctor" service to open up hierarchical diagnosis and treatment
Time of Update: 2021-06-30
Zhang Doudou, Secretary of the Party Branch of Changtong Community Health Service Center in Nanguan District, Changchun City, said that the community family doctor's contracted service mainly promotes basic service packages, including the establishment of health files for residents, free health consultations from residents, and health knowledge lectures.
-
Functional cosmetics are also insured, how can "drugs and cosmetics" be sold under the new supervision?
Time of Update: 2021-06-30
In addition to the late start, another reason is that China's functional cosmetics market is mainly online, and the offline market based on professional pharmacies is still in an earlier stage of development .
-
Red blood cell maturation agent Rotexip significantly improves anemia and quality of life in patients with transfusion-independent β-thalassemia
Time of Update: 2021-06-30
The purpose of this study is to evaluate the efficacy and safety of the world's first red blood cell maturation agent rotexip combined with best supportive therapy for the treatment of adult non-transfusion dependent (NTD) β-thalassemia .
-
The "Medical Security Law" is coming soon!
Time of Update: 2021-06-29
Medical Network News on June 17 Another medical insurance law/law is about to come out! On June 15, the National Medical Insurance Administration issued an announcement on the "Medical Security Law
-
The second batch of lists announced!
Time of Update: 2021-06-29
Medical Network, June 18 News On June 16, the National Health Commission issued the "Notice on Identifying the Second Batch of National Demonstration Cities for Comprehensive Reform of Public Hospita
-
In order to further facilitate the treatment of the elderly, the National Health Commission has launched ten measures
Time of Update: 2021-06-29
Fifth, the implementation of "one-stop" service for admission and discharge Encourage qualified medical institutions to establish a comprehensive service center or window for hospital admission, and handle all kinds of matters including information registration, hospitalization payment, and pre-hospital inspection appointments .
